AgeX Therapeutics News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

14.11.23	AgeX Therapeutics Reports Third Quarter 2023 Financial Results (Businesswire)
24.10.23	SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NXGN, SMMF, RPT, AGE (PR Newswire)
19.10.23	SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SMMF, RPT, AGE (PR Newswire)
10.10.23	SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AGE, NXGN, AVTA, SPLK (PR Newswire)
05.10.23	SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AVID, SMMF, RPT, AGE (PR Newswire)
26.09.23	SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NXGN, RPT, THRN, AGE (PR Newswire)
19.09.23	SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ABCM, AGE, ACER, NXGN (PR Newswire)
13.09.23	SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates WRK, AGE, ACER (PR Newswire)
06.09.23	SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates THRN, ABCM, AGE, ACER (PR Newswire)
30.08.23	Serina Therapeutics and AgeX Therapeutics Enter into Merger Agreement (Businesswire)
14.08.23	AgeX Therapeutics Reports Second Quarter 2023 Financial Results (Businesswire)
25.07.23	AgeX Therapeutics Closes $36,000,000 Debt Exchange for Preferred Stock (Businesswire)
21.07.23	AgeX Therapeutics Announces $36,000,000 Debt Exchange for Preferred Stock (Businesswire)
23.05.23	AgeX Therapeutics Announces Appeal of NYSE American Determination (Businesswire)
12.05.23	AgeX Therapeutics Reports First Quarter 2023 Financial Results (Businesswire)
31.03.23	AgeX Therapeutics Reports Fourth Quarter and Annual 2022 Financial Results (Businesswire)
25.11.22	AgeX Therapeutics Receives Extension of Time to Attain Compliance With Stock Exchange Continued Listing Requirements (Businesswire)
10.11.22	AgeX Therapeutics Reports Third Quarter 2022 Financial Results (Businesswire)
12.08.22	AgeX Therapeutics Reports Second Quarter 2022 Financial Results (Businesswire)
18.05.22	Dr. Joanne Hackett Appointed Chairperson of AgeX Board of Directors (Businesswire)
13.05.22	AgeX Therapeutics Reports First Quarter 2022 Financial Results (Businesswire)
29.03.22	AgeX Therapeutics Reports Fourth Quarter and Annual 2021 Financial Results (Businesswire)
03.01.22	Pre-market Movers: CELZ, AFI, BLCT, AGE, PTE… (RTTNews)
16.08.21	MÄRKTE USA/Uneinheitlich - Dow und S&P-500 mit neuen Rekordhochs (Dow Jones)
16.08.21	MÄRKTE USA/Schwache Daten aus China und USA animieren zu Gewinnmitnahmen (Dow Jones)
16.08.21	MÄRKTE USA/Schwache Daten aus China und USA drücken (Dow Jones)
16.08.21	MÄRKTE USA/Wall Street mit schwachen China-Daten leichter erwartet (Dow Jones)
16.08.21	MARKT USA/Wall Street mit schwachen China-Daten leichter erwartet (Dow Jones)
17.05.21	AgeX Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update (Businesswire)
31.03.21	AgeX Therapeutics Reports Fourth Quarter and Annual 2020 Financial Results and Provides Business Update (Businesswire)
12.03.21	AgeX Announces Preprint Article Relating to Regeneration, Aging, and Cancer (Businesswire)
10.03.21	AgeX Therapeutics to Collaborate with The Ohio State University to Generate Proof-of-Concept Animal Data for AgeX’s Brown Adipose Tissue (BAT) Cell Therapy Candidate for Diabetes and Obesity (Businesswire)
02.03.21	AgeX Therapeutics and LyGenesis to Negotiate Merger Agreement (Businesswire)
22.12.20	AgeX Therapeutics, Inc. Announces That Its Annual Meeting of Stockholders Will Be Conducted Online Only (Businesswire)
16.11.20	AgeX Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update (Businesswire)
28.10.20	AgeX Therapeutics Sublicenses Stem Cell Line ESI-053 to ImStem Biotechnology for Development of Cell Therapy Candidate IMS001 for COVID-19 and Acute Respiratory Distress Syndrome (Businesswire)
13.10.20	ATXI Plunges On Thumbs-down, VYGR's Huntington's Disease Trial On Hold, Deal Or No Deal For SURF? (RTTNews)
12.10.20	Pre-market Movers In Healthcare Sector: IMRN, AKBA, MDGS, ENLV... (RTTNews)
09.10.20	Pre-market Movers In Healthcare Sector: SELB, GNMK, IMRN, AGE, ACHV… (RTTNews)
08.10.20	Pre-market Movers In Healthcare Sector: CDNA, IMTX, REGN, CRSP, TLC... (RTTNews)
09.09.20	AgeX Therapeutics and Lineage Cell Therapeutics Announce Expansion of Agreement Related to ESI Clinical-grade Pluripotent Stem Cell Lines for Therapeutic Purposes (Businesswire)
03.09.20	Pre-market Movers In Healthcare Sector: SNSS, NNVC, STRO, FLGT, LPCN... (RTTNews)
14.08.20	AgeX Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business Update (Businesswire)
16.06.20	AgeX Therapeutics and Pluristyx Announce Manufacturing, Marketing, and Distribution Agreement to Expand Access to Clinical-Grade Human Pluripotent Stem Cells for Therapeutic Applications (Businesswire)
05.06.20	AgeX Therapeutics Receives Stock Exchange Deficiency Letter (Businesswire)
03.06.20	AGEN, AGE To Battle Coronavirus, BCLI Awaits ALS Trial Data, FDA Delays Decision On NVS' Drug (RTTNews)
02.06.20	AgeX Expands Relationship With ImStem Regarding IMS001 To Include COVID-19, ARDS (RTTNews)
02.06.20	AgeX Therapeutics and ImStem Biotechnology Sign Non-Binding Letter of Intent Regarding Investigational MSC Candidate IMS001 for COVID-19 and Other Causes of ARDS (Businesswire)
29.05.20	AgeX Therapeutics and Sernova to Collaborate to Engineer Universal Locally Immune Protected Cell Therapies for Type I Diabetes and Hemophilia A (Businesswire)
21.05.20	AgeX Therapeutics, Inc. Appoints Andrea Park as Chief Financial Officer (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Sonova Hldg	302.80	1.30 %	K V
Alcon	76.88	0.65 %	K V
Sika	218.00	0.37 %	K V
Kuehne+Nagel Int	202.60	-0.20 %	K V
Logitech Intl	78.28	-0.33 %	K V
ABB	49.25	-1.44 %	K V
Holcim	87.68	-1.55 %	K V
Zurich Insur Gr	531.20	-1.63 %	K V
Roche Hldg G	267.20	-1.69 %	K V
UBS Group	29.78	-1.94 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu AgeX Therapeutics Inc Registered Shs

Aktien Top/Flop

Meistgelesene Nachrichten